Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.92 Million SEK | -50.25% |
| 2022 | 3.87 Million SEK | 113.51% |
| 2021 | 1.81 Million SEK | -28.64% |
| 2020 | 2.54 Million SEK | 770.55% |
| 2019 | 292 Thousand SEK | -63.13% |
| 2018 | 792 Thousand SEK | -36.64% |
| 2017 | 1.25 Million SEK | -28.57% |
| 2016 | 1.75 Million SEK | -37.19% |
| 2015 | 2.78 Million SEK | 18.2% |
| 2014 | 2.35 Million SEK | -86.32% |
| 2013 | 17.22 Million SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | - SEK | -100.0% |
| 2024 Q1 | 1.69 Million SEK | -12.25% |
| 2024 Q2 | 1.45 Million SEK | -13.9% |
| 2023 Q3 | 2.22 Million SEK | -10.35% |
| 2023 FY | 1.92 Million SEK | -50.25% |
| 2023 Q2 | 2.48 Million SEK | -22.05% |
| 2023 Q1 | 3.18 Million SEK | -17.79% |
| 2023 Q4 | 1.92 Million SEK | -13.39% |
| 2022 Q4 | 3.87 Million SEK | -16.48% |
| 2022 Q3 | 4.63 Million SEK | -14.85% |
| 2022 FY | 3.87 Million SEK | 113.51% |
| 2022 Q1 | 6.19 Million SEK | 241.73% |
| 2022 Q2 | 5.44 Million SEK | -12.15% |
| 2021 Q4 | 1.81 Million SEK | -9.12% |
| 2021 Q1 | 2.41 Million SEK | -4.92% |
| 2021 Q2 | 6.27 Million SEK | 159.62% |
| 2021 Q3 | 1.99 Million SEK | -68.19% |
| 2021 FY | 1.81 Million SEK | -28.64% |
| 2020 FY | 2.54 Million SEK | 770.55% |
| 2020 Q4 | 2.54 Million SEK | -4.69% |
| 2020 Q3 | 2.66 Million SEK | -1.51% |
| 2020 Q1 | 208 Thousand SEK | -28.77% |
| 2020 Q2 | 2.7 Million SEK | 1201.92% |
| 2019 Q4 | 292 Thousand SEK | -29.98% |
| 2019 Q1 | 667 Thousand SEK | -15.78% |
| 2019 FY | 292 Thousand SEK | -63.13% |
| 2019 Q3 | 417 Thousand SEK | -23.06% |
| 2019 Q2 | 542 Thousand SEK | -18.74% |
| 2018 Q2 | 1.04 Million SEK | -10.71% |
| 2018 Q3 | 917 Thousand SEK | -12.0% |
| 2018 Q4 | 792 Thousand SEK | -13.63% |
| 2018 FY | 792 Thousand SEK | -36.64% |
| 2018 Q1 | 1.16 Million SEK | -6.64% |
| 2017 Q4 | 1.25 Million SEK | -9.09% |
| 2017 FY | 1.25 Million SEK | -28.57% |
| 2017 Q3 | 1.37 Million SEK | 14.87% |
| 2017 Q2 | 1.19 Million SEK | -26.34% |
| 2017 Q1 | 1.62 Million SEK | -7.14% |
| 2016 Q2 | 2 Million SEK | 0.0% |
| 2016 Q4 | 1.75 Million SEK | -6.67% |
| 2016 FY | 1.75 Million SEK | -37.19% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q3 | 1.87 Million SEK | -6.25% |
| 2015 Q1 | 1.96 Million SEK | -16.67% |
| 2015 FY | 2.78 Million SEK | 18.2% |
| 2015 Q4 | 2.78 Million SEK | -21.98% |
| 2015 Q3 | 3.57 Million SEK | 127.16% |
| 2015 Q2 | 1.57 Million SEK | -19.96% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | 2.35 Million SEK | 0.0% |
| 2014 FY | 2.35 Million SEK | -86.32% |
| 2013 Q4 | 17.22 Million SEK | 0.0% |
| 2013 FY | 17.22 Million SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.868% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.868% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 95.445% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.89% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 96.66% |
| CellaVision AB (publ) | 28.66 Million SEK | 93.277% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -764.126% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -9.926% |
| Duearity AB (publ) | 2.94 Million SEK | 34.456% |
| Dignitana AB (publ) | 6.07 Million SEK | 68.29% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 16.217% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.951% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 69.667% |
| Iconovo AB (publ) | 4.9 Million SEK | 60.729% |
| Integrum AB (publ) | 4.84 Million SEK | 60.223% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -835.328% |
| Mentice AB (publ) | 2.14 Million SEK | 10.121% |
| OssDsign AB (publ) | 214 Thousand SEK | -800.467% |
| Paxman AB (publ) | 2.53 Million SEK | 23.894% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 35.852% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 53.888% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 89.966% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -90.415% |
| Senzime AB (publ) | 8.57 Million SEK | 77.536% |
| SpectraCure AB (publ) | 4.39 Million SEK | 56.175% |
| Stille AB | 38.06 Million SEK | 94.938% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.897% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 90.897% |